Wall Street brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post earnings of $0.61 per share for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with the lowest EPS estimate coming in at $0.56 and the highest estimate coming in at $0.67. Teva Pharmaceutical Industries reported earnings of $0.53 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The firm is expected to report its next earnings results on Wednesday, February 12th.
On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.38 per share for the current year, with EPS estimates ranging from $2.25 to $2.48. For the next year, analysts anticipate that the company will post earnings of $2.52 per share, with EPS estimates ranging from $2.36 to $2.76. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. The business had revenue of $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.78 EPS.
TEVA has been the subject of a number of recent research reports. Wolfe Research initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They set a “peer perform” rating and a $9.00 price target for the company. Wells Fargo & Co cut their price objective on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Morgan Stanley downgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $16.00 to $6.00 in a research note on Monday, July 15th. Guggenheim began coverage on Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They set a “neutral” rating for the company. Finally, UBS Group set a $8.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Friday, August 16th. Six analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.78.
Several large investors have recently made changes to their positions in the stock. AdvisorNet Financial Inc lifted its holdings in Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after purchasing an additional 1,525 shares in the last quarter. First Interstate Bank purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $28,000. Motco purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $28,000. Lindbrook Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 76.6% in the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock worth $31,000 after purchasing an additional 1,935 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $32,000. Institutional investors own 58.21% of the company’s stock.
Shares of Teva Pharmaceutical Industries stock traded up $0.83 during trading hours on Tuesday, reaching $9.30. 34,192,717 shares of the stock traded hands, compared to its average volume of 16,922,125. The company has a 50 day moving average price of $7.51 and a 200 day moving average price of $8.90. The firm has a market capitalization of $9.32 billion, a price-to-earnings ratio of 3.32, a P/E/G ratio of 0.89 and a beta of 1.73. Teva Pharmaceutical Industries has a one year low of $6.07 and a one year high of $23.97. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.73.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Which market index is the best?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.